The aim of this study is to describe the evolution of multimorbidity.
Study Design and Setting
Data from 1854 South Australians who participated in the North West Adelaide longitudinal Health Study(NWAHS) was collected between baseline (2000–2002) and follow-up (2008–2010). Status for eight chronic diseases (CDs) was determined by biomedical measurement or self-report. Chronic disease (CD) mean age of occurrence and order of appearance was investigated.
The prevalence of multimorbidity increased from 32% to 64% during the 7.8±1.1 years of follow-up. The estimated mean age of onset of a new CD was significantly older for hypertension, cardiovascular disease (CVD) and chronic obstructive pulmonary disease (COPD) and younger for hypercholesterolemia, asthma and other mental problem. Hypercholesterolemia was more likely to develop as a first than as a subsequent CD (39%vs.16%, p<0.0001) while CVD (1%vs.5%, p<0.0001), diabetes (5%vs.11%, p<0.001) and COPD (6%vs.16%, p<0.0001) were less likely. The presence of mood disorders at baseline was associated with an increased risk of developing other mental disorders (36%vs.12%, p<0.0001), diabetes (18%vs.9%, p<0.01) and asthma (30%vs.21%, p<0.05).
Longitudinal data could be used to study the evolution of multimorbidity and could provide information on CDs mean age of occurrence, order of appearance and impact on the development of future CDs.
Citation: Ruel G, Lévesque J-F, Stocks N, Sirois C, Kroger E, et al. (2014) Understanding the Evolution of Multimorbidity: Evidences from the North West Adelaide Health Longitudinal Study (NWAHS). PLoS ONE 9(5): e96291. doi:10.1371/journal.pone.0096291
Editor: J. Jaime Miranda, Universidad Peruana Cayetano Heredia, Peru
Received: October 7, 2013; Accepted: April 7, 2014; Published: May 5, 2014
Copyright: © 2014 Ruel et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Guillaume Ruel is the awardee of a postdoctoral training award from from Fonds de recherche du Québec – Sante and Jean-Frederic Levesque is an awardee of a Junior 1 clinical scientist award from Fonds recherché Quebec – Sante. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Today, chronic diseases (CDs) are highly prevalent and constitute the leading cause of death in the world . However, advances in the management of CDs has slowed the progression of diseases and delayed related death in developed countries. Such changes have led to an increase in multimorbidity , , , , mainly defined as the presence of two or more medical conditions in an individual . In general, multimorbidity includes only CDand its prevalence increases with age ,  and social deprivation , . It has been shown to be associated with increased medical consultation, prescription, psychological distress, emergency utilization, hospital length of stay, and mortality rates , , , .
Multimorbidity is part of a continuum ranging from healthy status, development of a single CDand then progression to multimorbidity with the addition of a further CD. The term ‘evolution of multimorbidity’ could be used to describe this whole process. The knowledge retrieved from a study of evolution of multimorbidity has the potential to identify populations at high risk of developing multimorbidity as well as repartitioning CDs across this continuum. Few studies , , ,  have examined multimorbidity from a longitudinal perspective. Those studies focused mostly on the impact of CDs on disability, functional decline and mortality  or its relationship with nutrition . In addition to the strength of association between CDs at a specific time point (e.g. observed over expected ratio) , a longitudinal follow-up design is rarely used in the context of multimorbidity and could help understand causality . To the best of our knowledge, no study has used a longitudinal study design to investigate the evolution of multimorbidity. This study aims to characterize evolution of multimorbidity by 1) characterizing the magnitude of the evolution of the prevalence of multimorbidity through time, 2) determining the order in which CDs appear and 3) identifying CDs present at baseline which are associated with an increased risk of developing other CDs.
The North West Adelaide Health Longitudinal Study (NWAHS) is a representative population sample of people aged 18 years or older living in the north western suburbs of Adelaide, South Australia (regional population 0.6 million) and covers a broad range of socioeconomic areas. The study's purpose is to investigate the prevalence of chronic conditions and associated health-related risk factors, and to monitor progression of diseases over time in order to help plan health care provision. The sample is representative of the community profile of Adelaide , ,  and has been described previously in detail , . Briefly, between 2000 and 2002, 4060 adults completed a telephone interview, self-completed questionnaire and clinic biomedical assessment (including blood sample). This represents 50% of the people invited to take part in the study. Persons aged ≥18 years from households selected at random from the electronic white pages directory were eligible. Respondents completed a self-report questionnaire related to health status and additional demographic details and underwent clinical assessment, including measurement of blood pressure, height, weight, fasting glucose and lipid levels. Stage 2 (2004 to 2006) and Stage 3 (2008 to 2010) included a Computer Assisted Telephone Interview (CATI), a self completed questionnaire and a biomedical examination at a clinic. For Stage 2, 3564 of the participants were interviewed and/or completed a questionnaire and 81.0% of the eligible sample (n = 3205) attended a clinic appointment. For Stage 3, 2871 of the participants were interviewed and/or completed a questionnaire and 2487 individuals attended clinics. Overall, complete clinical and self reports information at each phase and for every CD was available for 1854 individuals (46% of the baseline sample). In order to maximize follow-up duration, the data from stage 1 and 3 were used, but data from stage 2 also contributed to establishing CD status at stage 3. Stage 1 and 3 are considered as baseline and follow-up throughout this article. A recently published paper by our group directly addresses the representativeness of the stage 3 cohort . Briefly, it was found that compared to the census, and a sample of the population surveyed by CATI over the same period, those in the stage 3 of NWAHS were older, more likely to have a trade or certificate, to be employed, to be a non-smoker and to have a higher income. No significant differences were found in gender proportion and alcohol consumption. Requests for de-identified data can be sent to the Chief investigator (firstname.lastname@example.org) or the study co-ordinator (Janet.email@example.com). The study was approved by institutional ethics committees of the North West Adelaide Health Service, and all subjects gave written informed consent.
Physical and Socio-demographic characteristics
Height was measured to the nearest 0.5 centimetres using a stadiometer, and weight to the nearest 0.1 kilogram in light clothing and without shoes using standard digital scales. Body mass index (BMI) was calculated as weight (kg)/height (m)2. Information on socio-demographic and other lifestyle factors were also collected (Table 1).
Chronic disease status assessments
CD status was determined for the following eight conditions: asthma, cardiovascular disease and stroke (CVD), chronic obstructive pulmonary disease (COPD), diabetes, mood and anxiety disorders, any other mental disorders, hypercholesterolemia and hypertension. Asthma, COPD, diabetes, hypercholesterolemia and hypertension were determined at the clinic visit. A fasting blood test was performed to determine total cholesterol and glucose levels (FPG). A person was deemed to have diabetes if they self-reported having ever been told by a doctor they had the condition, self-reported utilisation of glucose lowering drugs or by measurement at the clinic (FPG≥7.0 mmol/L) , . High cholesterol was defined as total blood cholesterol ≥5.5 mmol/L or self report of cholesterol lowering drugs . Two blood pressure measurements were taken five to ten minutes apart using a standard, calibrated blood pressure sphygmomanometer, while the participant was relaxed and seated. The average of these two recorded measures was used in the analyses. High blood pressure was defined as systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg or the self-reported use of drugs to lower blood pressure. Participants were tested for asthma and COPD at the clinic visit by spirometry before and after the use of a beta agonist. A positive COPD case was present if FEV1/FVC<70% and for asthma if FEV1≥12% and >200 ml or absolute change greater or equal to 400 ml from pre salbutamol to post salbutamol , . Status for asthma was determined using clinical and self-report while COPD was mainly based on clinical measurement as previously described , . Participants self-reported if they had ever been told by a doctor they had CVD (heart attack, stroke, angina) or a mental health condition (anxiety, depression or other mental health problem). Mental health condition was then split between mood and anxiety disorders and other mental disorders. An individual having a diagnosis for a CD was considered as having it for every phase afterwards.
Mean incident age of onset of a CD developed during the follow-up period was calculated based on age at the time of follow-up. Mean incident age of onset of a CD was compared with those that developed another CD by using independent sample student t test. For the population that developed a CD, multinomial logistic regression (MLR) was used to determine significant differences in the count and individual proportion of CDs developed between those who were healthy or had at least one CD at baseline. Among those with a CD at baseline, MLR was also used to determine significant differences in the count and proportions of those with CDs between who developed CDs or not. Difference in CDs developed by the subgroups with asthma or mood and anxiety disorders at baseline was determined using MLR. The control group consisted of those who developed another CD. All MLR analyses were undertaken for crude; adjusted by age and sex; and adjusted for age, sex, BMI status, marital status, working status, annual income and education. For all the MLR analyses, unadjusted odds ratios were also determined. Unless stated otherwise, (95%) confidence intervals are presented in the figures and standard deviation in the text while the p value found in the text is adjusted for both age and sex. All analyses were carried out using SPSS version 17.0 (SPSS, Inc., Chicago, IL, USA) and a p<0.05 was considered significant.
Description of the cohort
Baseline physical and socio-demographic characteristics of the cohort are described in Table 1. Briefly, the cohort (mean age ± standard deviation at baseline: 50±14 years old) included slightly more females (52%), people working (60%) and married (67%). The mean follow-up period of the 1854 individuals included in the cohort was 7.8±1.1 years.
Chronic diseases and multimorbidity status
CD status throughout the study is presented in Table 2. At baseline, among the 1854 participants, 1299 (70%) had at least one CD at baseline. The prevalence of multimorbidity doubled from baseline (32%; 95%CI: 30–34%) to follow-up (64%; 62–66%). Accordingly, the mean number of CDs per person increased from 1.12±0.99 to 2.09±1.30. At baseline, hypercholesterolemia and hypertension were the most common CDs with prevalences of 41% (39–43%) and 28% (26–30%) respectively. At follow-up, these prevalences increased to 64% (62–66%) and 48% (46–50%) respectively. During the study, a total of 1152 participants (62%; 60–64%) developed at least one CD while 473 (25%; 23–27%) developed at least two CDs. Among individuals without a CD at baseline, 30% (28–32%) stayed healthy (9% of the total cohort) while 70% (68–72%) developed at least one CD (21% of the cohort). Among the 1299 participants with at least one CD at baseline, 58% (56–60%) developed at least another one (41% of the cohort) while 42% (40–44%) did not (29% of the cohort).
Mean age of occurrence of individual chronic diseases developed during the follow-up
Individuals who did not develop a CD (n = 702) were significantly younger than those that developed two (n = 339) or three CDs (n = 134) during the follow-up period (mean ± S.E., −4±1, p<0.0001 and −5±1, p<0.01 years old respectively). Among the 1152 participants that developed at least one CD, the mean age of onset of all newly developed CD was 59±13 years old. The mean age of occurrence of each newly developed individual CD was determined (Figure 1, panel A). When compared to this mean age of onset of all newly developed CDs, the mean age of onset was lower for hypercholesterolemia (−4±1 years, p<0.0001), other mental disorders (−4±1 years, p<0.0001) and asthma (−3±1 years, p<0.005). Conversely, COPD (+10±1 years, p<0.0001), CVD (+10±2 years, p<0.0001) and hypertension (+3±1 years, p<0.0001) were developed at an older age.
The Y axis of Panel A correspond to the estimated mean age (59) at which CD were developed during follow-up. Error bar from panel A are confidence interval (95%). The Light and dark gray bars correspond to CD developed as a first and a subsequent CD respectively * and §significantly different from the first CD group in every models and in the age and sex adjusted models respectively.
Comparison of baseline health status between chronic diseases developed during the follow-up
Among those who developed at least one new CD during the 7.8 years of follow-up (n = 1152), 1793 CDs were developed and 619 occurred in healthy individuals and 1174 in those who had at least one CD. The proportion of the total count of each CD developed in those who were healthy at baseline and those that had at least one CD is illustrated in Figure 1 (panel B). Hypercholesterolemia represented 23% of the sum of all CDs developed. Since an individual could develop more than one CD, the proportion of the cohort that acquired the disease during the follow-up was 39%. Among those that acquired hypercholesterolima, 62% were healthy individuals at baseline while only 24% had a CD at baseline (p<0.0001). There was no significant difference in the proportion of cases that developed asthma (19% vs. 22%) and other mental illness (13% vs. 16%) between individuals without and with a CD at baseline in the crude model but this difference reached significance in both adjusted models (p<0.01 and p<0.05 respectively). The odds ratio of those with a CD at baseline over those without was 4.04 (1.92–8.51), 2.37 (1.42–3.94) and 3.01 (2.09–4.36) for CVD, diabetes and COPD new cases compared to the total number of CDs developed. Also, among those who developed at least one CD during the follow-up, 8%, 11% and 25% of the individuals with a CD at baseline acquired CVD, diabetes and COPD respectively while the proportions were only 2%, 5% and 10% for those without.
Identification of baseline chronic diseases associated with an increased the risk to develop chronic disease during follow-up
Sixty percent of the population with at least one CD at baseline developed at least another one during the 7.8 year of follow-up (Figure 2). The proportion that developed CDs was significantly lower in those with hypercholesterolemia (52%, p<0.0001) or hypertension (53%, p<0.0001) at baseline. The proportion that developed another CD was significantly higher in those with asthma (65%, p<0.05) or mood and anxiety disorders (70%, p<0.0001) at baseline. As a consequence, the prevalence of asthma and mood and anxiety disorders at baseline were higher in those that developed a CD ((OR: 1.37 (95%CI: 1.02–1.86) and 1.76 (1.25–2.49) respectively) than in those that did not.
The X-axis correspond to the proportion (60%) of those that developed at least one CD during follow-up among those that had at least one CD at baseline. *significantly different from the mean proportion of individual that developed CD. Error bar are confidence interval (95%).
Chronic diseases more likely to be developed by those with asthma or depression at baseline
Since the presence of both asthma and mood and anxiety disorders at baseline was associated with an increased risk of developing another CD, the profile of CDs that those groups developed were explored comparing them with those who had another CD at baseline and that developed another CD (Table 3). Individuals with asthma at baseline had a higher risk of developing COPD (OR: 1.80; 95CI: 1.22–2.67) and hypercholesterolemia (2.19; 1.48–3.25). Those having mood and anxiety disorders at baseline were more likely to develop asthma (1.62; 1.05–2.49), diabetes (2.10; 1.23–3.57) and other mental disorders (4.18; 2.69–6.49).
Relationship between mean age of occurrence and order of appearance of chronic diseases developed during the follow-up
Relationship between mean age of occurrence of a CD and the order of appearance of a CD, expressed as the ratio of a CD to be developed as a subsequent over a first CD, is illustrated in Panel A of Figure 3. Briefly, hypercholesterolemia significantly occurs in younger persons and as a first CD while COPD and CVD occurs in older age groups after the occurrence of other CDs. While other mental disorders and asthma occurs at a younger age, they are as likely to occur as a first or as a subsequent CD. Diabetes is more likely to occur after the occurrence of another CD despite occurring closely to the mean age of occurrence of the eight CDs. The relationship between the mean age of occurrence and the proportion of participants with a specific CD at baseline to developing a CD during the follow-up is illustrated in Panel B of Figure 3. While occurring at a younger age, the proportion that developed other CDs is significantly higher among those with mood and anxiety disorder and those with asthma and lower for those with hypercholesterolemia at baseline.
This study contributes to the understanding of the evolution of multimorbidity using longitudinal data. Briefly, the main findings are: 1) Multimorbidity prevalence doubled over the 7.8 years of follow-up, 2) Individual CDs have different mean age of onset and order of appearance which are not always related and 3) some CDs are associated with an increased risk of developing other CDs(Figure 3, panel C).
Multimorbidity and its evolution during the study
Multimorbidity is a condition affecting an important proportion of the population , , . While multimorbidity has been shown to increase with age , , its longitudinal evolution is less investigated . The present study reports a multimorbidity prevalence of 32% (with a mean age of 50 years old) that doubled over a mean 7.8 years of follow-up to reach 64%. This important increase in multimorbidity prevalence is in line with a recent systematic review , that reported that multimorbidity prevalence increases with aging, with the highest rise between age 40 and 70. Therefore, the present study, using a longitudinal design, confirms the steep and important increased in the prevalence of multimorbidity with aging reported in cross sectional studies. Also, the proportion of those with at least one CD was found to be similar to those observed in general practitioner populations but higher than those estimated in the general population .
Mean age of onset of chronic diseases developed during follow-up
This study also presents differences in the mean age of onset for eight CDs in the same population. Briefly, the mean age of onset of asthma, hypercholesterolemia and other mental disorders is younger while COPD, CVD and hypertension is older. While mental disorders are known to occur at a young age , it is surprising that mood and anxiety disorders are not frequent in the younger age group, particularly considering that their respective mean age of onset has been previously estimated to be 11 years for anxiety and 30 years for mood disorders . The reported mean age of onset of diabetes, asthma and COPD are in line with previous publications , . The present observations result from incident cases from individuals over 18 years old and do not take into account the age of onset of CDs already present at baseline. Despite these limits, the mean age of onset is important in understanding the evolution of multimorbidity and can be used to compare factors associated with CD occurrence. To the best of our knowledge, the comparison of age of onset for multiple CDs with different aetiology has never been undertaken.
Integration of order of appearance and mean age of occurrence for different chronic diseases
Hypercholesterolemia is more likely to occur at a younger age and as a first CD. This is concordant with a previous study showing that this CD was not associated with multimorbidity in populations under 60 years old  and the role of the hypercholesterolemia in diabetes and CVD development . COPD and CVD had an older mean age of occurrence and were more than twice as likely to develop after other CDs. Conversely, hypertension, which also had an older mean age of occurrence, is not more likely to occur as a subsequent CD than as a first. Asthma and other mental illness, which occurs at a younger age, were more likely to develop in those with a previous CD in both models adjusted for age and sex. Briefly, hypercholesterolemia, mood and anxiety disorders, COPD and CVD have a corresponding mean age of occurrence and order of appearance but not the other CDs.
Hypertension and hypercholesterolemia decrease the risk of developing chronic diseases
Another finding of the present study is that the presence of hypertension and hypercholesterolemia at baseline was significantly associated with a lower risk of developing CDs. This could be explained, at least partly, by the fact that statins and blood pressure lowering drugs are known to delay the development of some CDs such as CVD and diabetes . While hypertension and hypercholesterolemia were associated with a decreased risk of developing other CDs, their high prevalence still makes them the most common CD developed in individuals with existing CDs.
Mood and anxiety disorders increase the risk of developing diabetes, asthma and other mental disorders
The presence of mood and anxiety disorders or asthma at baseline was associated with an increased risk of developing other CDs. Over a third of the individuals with a mood and anxiety disorder develop another mental health problem over 7.8 years. It is well known that mood and anxiety disorders could trigger numerous other mental conditions , . Mood and anxiety disorders are also associated with multiple physical conditions such as diabetes, CVD, cancer and asthma , , , , . In the present cohort, 18% of the individuals with mood and anxiety disorders developed diabetes over the 7.8 years of follow-up. This increase is twice the one observed in other individuals who developed at least another CD. Mood and anxiety disorders had previously been associated with diabetes ,  and its development . Among the mechanisms proposed to explain this association, the use of antidepressants, particularly tricyclics antidepressants and selective serotonin reuptake inhibitors, in individuals with mood and anxiety disorders has been associated with an increased risk of developing abdominal obesity and diabetes , , . While some work has been done to determine the impact of mood and anxiety disorders and its treatment on comorbidities , , not much has been undertaken to determine their actual impact on other CD development. In light of the present results showing an increased risk in individuals with mood and anxiety disorders to develop diabetes, other mental disorders and asthma, as well as its consequences on other CD management and related complications , , this study supports the development of new approaches to address this problem .
Asthma increases the risk of developing COPD and hypercholesterolemia
In the present study, those with asthma at baseline were more likely to develop COPD and hypercholesterolemia. While asthma has a younger age of onset, it is also associated with higher comorbidity rates . In the present study, over 30% of those that developed more than two CDs developed both hypercholesterolemia and asthma which suggest an association between those two CDs (data not shown). In support of this hypothesis, asthma has been related to a disorder in cholesterol metabolism , . However, much work needs to be done to better understand and support this hypothesis. During the 7.8 years of follow-up, over 35% of the individuals with asthma developed COPD. This is in line with a recently reported overlapping in both asthma and COPD that could be associated with more frequent and severe respiratory exacerbations despite a younger age and a reduced lifetime smoking history. In the present study, the younger age observed in this population supports this observation , , .
While data have been adjusted for risk factors such as age, sex, education, marital status, working status, annual income and BMI, some potential residual confounders, such as nutrition and sedentary lifestyle, could still have an impact on multimorbidity evolution . The number of CDs investigated in the present study (8) is also relatively small when compared to some multimorbidity studies . However, the diagnosis of most of those CDs is based on biomedical measurement which is more precise than most other data sources since it ensures consistency of measurement despite potential change in CD definition, identification and screening procedure. It also permits taking into account undiagnosed conditions which has been previously shown to be high for some CDs . In the present study, those having a CD were considered as having it for every phase afterward which could have the potential to include milder forms of CD such as milder hypertension which could be considered as solved with appropriate lifestyle modifications. Also, individuals that died during the follow-up are not included and this may bring an immortal bias. However, this study is focusing on the evolution of multimorbidity and not on the impact of CDs on mortality. The quality of the diagnosis, the 7.8 years longitudinal follow-up and the use of adapted control group are among the strengths of the study.
In summary, this study presents some of the first observations on the evolution of multimorbidity. This approach shows the importance of the increase in multimorbidity prevalence, that CDs occur at different ages, in different order of appearance and that their occurrence could have an impact on the development of other CDs.
Conceived and designed the experiments: GR JFL AWT. Analyzed the data: GR. Wrote the paper: GR JFL AWT. Provided feedback on experiment design and the writing of the manuscript: NS CS EK RA MD.
- 1. World Health Organisation (2011) Non communicable disease (NCD) profile.
- 2. Fortin M, Bravo G, Hudon C, Vanasse A, Lapointe L (2005) Prevalence of multimorbidity among adults seen in family practice. Ann Fam Med 3: 223–228. doi: 10.1370/afm.272
- 3. Fortin M, Stewart M, Poitras ME, Almirall J, Maddocks H (2012) A systematic review of prevalence studies on multimorbidity: toward a more uniform methodology. Ann Fam Med 10: 142–151. doi: 10.1370/afm.1337
- 4. Taylor AW, Price K, Gill TK, Adams R, Pilkington R, et al. (2010) Multimorbidity - not just an older person's issue. Results from an Australian biomedical study. BMC Public Health 10: 718. doi: 10.1186/1471-2458-10-718
- 5. Harrison C, Britt H, Miller G, Henderson J (2013) Prevalence of chronic conditions in Australia. PLoS One 8: e67494. doi: 10.1371/journal.pone.0067494
- 6. van den Akker M, Buntinx F, Knottnerus JA (1996) Comorbidity or multimorbidity what's in a name? A review of literature. European Journal of General Practice. pp. 65–70.
- 7. Salisbury C, Johnson L, Purdy S, Valderas JM, Montgomery AA (2011) Epidemiology and impact of multimorbidity in primary care: a retrospective cohort study. Br J Gen Pract 61: e12–21. doi: 10.3399/bjgp11x548929
- 8. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, et al. (2012) Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 380: 37–43. doi: 10.1016/s0140-6736(12)60240-2
- 9. Broemeling AM, Watson DE, Prebtani F (2008) Population patterns of chronic health conditions, co-morbidity and healthcare use in Canada: implications for policy and practice. Healthc Q 11: 70–76. doi: 10.12927/hcq.2008.19859
- 10. Librero J, Peiro S, Ordinana R (1999) Chronic comorbidity and outcomes of hospital care: length of stay, mortality, and readmission at 30 and 365 days. J Clin Epidemiol 52: 171–179. doi: 10.1016/s0895-4356(98)00160-7
- 11. Fortin M, Bravo G, Hudon C, Lapointe L, Dubois MF, et al. (2006) Psychological distress and multimorbidity in primary care. Ann Fam Med 4: 417–422.
- 12. Diederichs CP, Wellmann J, Bartels DB, Ellert U, Hoffmann W, et al. (2012) How to weight chronic diseases in multimorbidity indices? Development of a new method on the basis of individual data from five population-based studies. J Clin Epidemiol 65: 679–685. doi: 10.1016/j.jclinepi.2011.11.006
- 13. France EF, Wyke S, Gunn JM, Mair FS, McLean G, et al. (2012) Multimorbidity in primary care: a systematic review of prospective cohort studies. Br J Gen Pract 62: e297–307. doi: 10.3399/bjgp12x636146
- 14. Marengoni A, von Strauss E, Rizzuto D, Winblad B, Fratiglioni L (2009) The impact of chronic multimorbidity and disability on functional decline and survival in elderly persons. A community-based, longitudinal study. J Intern Med 265: 288–295. doi: 10.1111/j.1365-2796.2008.02017.x
- 15. Wong A, Boshuizen HC, Schellevis FG, Kommer GJ, Polder JJ (2011) Longitudinal administrative data can be used to examine multimorbidity, provided false discoveries are controlled for. J Clin Epidemiol 64: 1109–1117. doi: 10.1016/j.jclinepi.2010.12.011
- 16. Ruel G, Shi Z, Zhen S, Zuo H, Kroger E, et al. (2013) Association between nutrition and the evolution of multimorbidity: The importance of fruits and vegetables and whole grain products. Clin Nutr. In press. doi: 10.1016/j.clnu.2013.07.009
- 17. Schafer I (2012) Does multimorbidity influence the occurrence rates of chronic conditions? A claims data based comparison of expected and observed prevalence rates. PLoS One 7: e45390. doi: 10.1371/journal.pone.0045390
- 18. Grant JF, Chittleborough CR, Taylor AW, Dal Grande E, Wilson DH, et al. (2006) The North West Adelaide Health Study: detailed methods and baseline segmentation of a cohort for selected chronic diseases. Epidemiol Perspect Innov 3: 4.
- 19. Grant JF, Taylor AW, Ruffin RE, Wilson DH, Phillips PJ, et al. (2009) Cohort Profile: The North West Adelaide Health Study (NWAHS). Int J Epidemiol 38: 1479–1486. doi: 10.1093/ije/dyn262
- 20. Taylor AW, Dal Grande E, Gill T, Chittleborough CR, Wilson DH, et al. (2006) Do people with risky behaviours participate in biomedical cohort studies? BMC Public Health 6: 11.
- 21. Taylor AW, Dal Grande E, Grant J, Appleton S, Gill TK, et al. (2013) Weighting of the data and analytical approaches may account for differences in overcoming the inadequate representativeness of the respondents to the third wave of a cohort study. J Clin Epidemiol 66: 461–464. doi: 10.1016/j.jclinepi.2012.06.021
- 22. Diagnosis and classification of diabetes mellitus. Diabetes Care 27 Suppl 1: S5–S10. doi: 10.2337/diacare.27.2007.s5
- 23. Chittleborough CR, Baldock KL, Taylor AW, Phillips PJ (2006) Health status assessed by the SF-36 along the diabetes continuum in an Australian population. Qual Life Res 15: 687–694. doi: 10.1007/s11136-005-3570-8
- 24. AIHW (2010) Australia's health 2010. In: AIHW, editor. Canberra: AIHW.
- 25. Appleton SL, Adams RJ, Wilson DH, Taylor AW, Ruffin RE (2005) Spirometric criteria for asthma: adding further evidence to the debate. J Allergy Clin Immunol 116: 976–982. doi: 10.1016/j.jaci.2005.08.034
- 26. Wilson D, Adams R, Appleton S, Ruffin R (2005) Difficulties identifying and targeting COPD and population-attributable risk of smoking for COPD: a population study. Chest 128: 2035–2042. doi: 10.1378/chest.128.4.2035
- 27. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, et al. (2005) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62: 593–602. doi: 10.1001/archpsyc.62.6.593
- 28. Koopman RJ, Mainous AG 3rd, Diaz VA, Geesey ME (2005) Changes in age at diagnosis of type 2 diabetes mellitus in the United States, 1988 to 2000. Ann Fam Med 3: 60–63.
- 29. O'Donnell DE, Aaron S, Bourbeau J, Hernandez P, Marciniuk D, et al. (2003) Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease—2003. Can Respir J 10 Suppl A: 11A–65A.
- 30. Fuchs FD, Fuchs SC, Moreira LB, Gus M (2012) Proof of concept in cardiovascular risk: the paradoxical findings in blood pressure and lipid abnormalities. Vasc Health Risk Manag 8: 437–442. doi: 10.2147/vhrm.s32585
- 31. Vaidyanathan U, Patrick CJ, Iacono WG (2011) Patterns of comorbidity among mental disorders: a person-centered approach. Compr Psychiatry 52: 527–535. doi: 10.1016/j.comppsych.2010.10.006
- 32. Gadermann AM, Alonso J, Vilagut G, Zaslavsky AM, Kessler RC (2012) Comorbidity and disease burden in the National Comorbidity Survey Replication (NCS-R). Depress Anxiety 29: 797–806. doi: 10.1002/da.21924
- 33. Sinnige J, Braspenning J, Schellevis F, Stirbu-Wagner I, Westert G, et al. (2013) The prevalence of disease clusters in older adults with multiple chronic diseases - a systematic literature review. PLoS One 8: e79641. doi: 10.1371/journal.pone.0079641
- 34. Ceretta LB, Reus GZ, Abelaira HM, Jornada LK, Schwalm MT, et al. (2012) Increased prevalence of mood disorders and suicidal ideation in type 2 diabetic patients. Acta Diabetol. doi: 10.1007/s00592-012-0435-9
- 35. Grigsby AB, Anderson RJ, Freedland KE, Clouse RE, Lustman PJ (2002) Prevalence of anxiety in adults with diabetes: a systematic review. J Psychosom Res 53: 1053–1060. doi: 10.1016/s0022-3999(02)00417-8
- 36. Roy-Byrne PP, Davidson KW, Kessler RC, Asmundson GJ, Goodwin RD, et al. (2008) Anxiety disorders and comorbid medical illness. Gen Hosp Psychiatry 30: 208–225. doi: 10.1016/j.genhosppsych.2007.12.006
- 37. Jani BD, Purves D, Barry S, Cavanagh J, McLean G, et al. (2013) Challenges and implications of routine depression screening for depression in chronic disease and multimorbidity: a cross sectional study. PLoS One 8: e74610. doi: 10.1371/journal.pone.0074610
- 38. Golden SH, Lazo M, Carnethon M, Bertoni AG, Schreiner PJ, et al. (2008) Examining a bidirectional association between depressive symptoms and diabetes. JAMA 299: 2751–2759. doi: 10.1001/jama.299.23.2751
- 39. Andersohn F, Schade R, Suissa S, Garbe E (2009) Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry 166: 591–598. doi: 10.1176/appi.ajp.2008.08071065
- 40. Chen Y, Patel NC (2010) Long term antidepressant use linked to increased risk of diabetes. Evid Based Ment Health 13: 30. doi: 10.1136/ebmh.13.1.30
- 41. Roberts RG, Gask L, Arndt B, Bower P, Dunbar J, et al. (2012) Depression and diabetes: the role and impact of models of health care systems. J Affect Disord 142 Suppl: S80–88 doi: 10.1016/s0165-0327(12)70012-5
- 42. Whalley B, Thompson DR, Taylor RS (2012) Psychological Interventions for Coronary Heart Disease: Cochrane Systematic Review and Meta-analysis. Int J Behav Med. doi: 10.1007/s12529-012-9282-x
- 43. Lustman PJ, Anderson RJ, Freedland KE, de Groot M, Carney RM, et al. (2000) Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 23: 934–942. doi: 10.2337/diacare.23.7.934
- 44. Anderson RJ, Grigsby AB, Freedland KE, de Groot M, McGill JB, et al. (2002) Anxiety and poor glycemic control: a meta-analytic review of the literature. Int J Psychiatry Med 32: 235–247. doi: 10.2190/klgd-4h8d-4ryl-twq8
- 45. Adams RJ, Wilson DH, Taylor AW, Daly A, Tursan d'Espaignet E, et al. (2006) Coexistent chronic conditions and asthma quality of life: a population-based study. Chest 129: 285–291. doi: 10.1378/chest.129.2.285
- 46. Fessler MB, Massing MW, Spruell B, Jaramillo R, Draper DW, et al. (2009) Novel relationship of serum cholesterol with asthma and wheeze in the United States. J Allergy Clin Immunol 124: 967–974. doi: 10.1016/j.jaci.2009.08.005
- 47. Misso NL, Brooks-Wildhaber J, Ray S, Vally H, Thompson PJ (2005) Plasma concentrations of dietary and nondietary antioxidants are low in severe asthma. Eur Respir J 26: 257–264. doi: 10.1183/09031936.05.00006705
- 48. Kim TB, Oh YM, Chang YS, Cho YS, Jang AS, et al. (2012) The reality of an intermediate type between asthma and COPD in practice. Respir Care 57: 1248–1253. doi: 10.4187/respcare.01232
- 49. Hardin M, Silverman EK, Barr RG, Hansel NN, Schroeder JD, et al. (2011) The clinical features of the overlap between COPD and asthma. Respir Res 12: 127. doi: 10.1186/1465-9921-12-127
- 50. Gibson PG, Simpson JL (2009) The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax 64: 728–735. doi: 10.1136/thx.2008.108027
- 51. Chittleborough CR, Burke MJ, Taylor AW, Wilson DH, Phillips PJ, et al. (2009) Medicare-related service use and costs among people with diagnosed and undiagnosed diabetes and respiratory conditions. Aust Health Rev 33: 107–116. doi: 10.1071/ah090107